NA
LXRX icon

NewEdge Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History

NewEdge Advisors’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5
Closed -$2 – 4087
2025
Q1 		$2 Hold
5
– – ﹤0.01% 3940
2024
Q4 		$4 Buy
+5
New +$6 ﹤0.01% 3883
2017
Q3 		– Sell
-64
Closed -$1.02K – 796
2017
Q2 		$1.02K Buy
+64
New +$991 ﹤0.01% 1350

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NewEdge Advisors's LXRX Position: Q2 2025 in Review

NewEdge Advisors sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2025, closing a stake of 5 shares — an estimated $2 sold.

NewEdge Advisors first reported a position in LXRX in Q2 2017 and held it in 3 quarters. The position peaked at $1.02K in Q2 2017. 123 funds tracked by Wall St. Rank hold LXRX as of Q2 2025.

  • NewEdge Advisors reported no remaining Lexicon Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • NewEdge Advisors sold 5 Lexicon Pharmaceuticals shares in Q2 2025, an estimated $2.
  • NewEdge Advisors first reported a position in Lexicon Pharmaceuticals in Q2 2017 and held it in 3 quarters.
  • NewEdge Advisors's Lexicon Pharmaceuticals position peaked at $1.02K in Q2 2017.
  • 123 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2025.

Based on NewEdge Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.